Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 116,265 |
|
|||||
| News | - |
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| HUTCHMED China Limited | HCM | NASDAQ | Depository Receipt |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.58 | 3.15% | 18.99 | 17:30:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 18.75 | 18.54 | 19.23 | 18.99 | 18.41 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume |
|---|---|---|---|---|
| 1,889 | 116,265 | 18.97 | 2,205,002 | - |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:00:16 | priorref | 100 | 18.99 | USD |
HUTCHMED China Limited Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 0 | 0.00 | - | 838M | 100.78M | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
News HUTCHMED China
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
HCM Historical
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Year | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 5 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Its reportable segments include the innovation platform and commercial platform. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The commercial platform includes a prescription drugs business and a consumer health business for over-the-counter drugs. |
